Riluzole is a benzothiazole derivative and glutamate antagonist primarily indicated for the treatment of amyotrophic lateral sclerosis (ALS) to help manage this progressive neurodegenerative condition.… Read more









![Chemical structure of [4-(Trifluoromethyl)phenyl]thiourea](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1736-72-7-4-Trifluoromethylphenylthiourea.png&w=3840&q=75)











Riluzole is a benzothiazole derivative and glutamate antagonist primarily indicated for the treatment of amyotrophic lateral sclerosis (ALS) to help manage this progressive neurodegenerative condition. By blocking voltage-gated sodium channels, the drug works to reduce excitotoxicity in motor neurons. To support rigorous pharmaceutical development, this category includes a comprehensive range of Riluzole reference standards essential for analytical testing and quality control. Laboratories utilize these materials—including synthetic impurities, process-related byproducts, and stable isotope-labelled compounds—for precise impurity profiling and method validation. The selection also features key metabolites, such as N-hydroxy and glucuronide derivatives, which are critical for monitoring metabolic pathways and ensuring regulatory compliance. These analytical tools allow for the accurate identification and quantification of related substances, ensuring the structural integrity and consistent quality of the drug throughout its development and manufacturing lifecycle.